Online citations, reference lists, and bibliographies.
← Back to Search

Combination Of Raltitrexed And Oxaliplatin Is An Active Regimen In Malignant Mesothelioma: Results Of A Phase II Study.

K. Fizazi, H. Doubre, T. Le Chevalier, A. Rivière, Juliette Viala, C. Daniel, L. Robert, P. Barthélémy, A. Fandi, P. Ruffié
Published 2003 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSE The aim of this open-label phase II study was to evaluate the activity of raltitrexed (Tomudex; AstraZeneca, Cergy, France) and oxaliplatin combination therapy in patients with diffuse malignant pleural mesothelioma. PATIENT AND METHODSs: Fifteen pretreated and 55 chemotherapy-naive patients (median age, 60 years; World Health Organization performance status of < or = 2) were enrolled. Most patients (66%) had advanced disease. Patients received raltitrexed 3 mg/m2 followed by oxaliplatin 130 mg/m2 every 3 weeks. RESULTS Twenty-four patients (34%) were classified as having a poor prognosis. In the overall study population, 14 patients (20%) had a partial response, and 32 patients (46%) had stable disease. The symptomatic response rates were as follows: shortness of breath, 36%; pain, 30%; activity, 23%; appetite, 21%; and asthenia, 20%. Median time to disease progression was 18 weeks (95% confidence interval [CI], 13 to 22 weeks). In chemotherapy-naive patients, median survival was 31 weeks (95% CI, 23 to 40 weeks) from the start of treatment and 49 weeks (95% CI, 40 to 52 weeks) from diagnosis of mesothelioma. In pretreated patients, median survival was 44 weeks (95% CI, 24 to 40 weeks) from the start of treatment and 226 weeks (95% CI, 63 to 292 weeks) from the diagnosis of mesothelioma. Overall 1-year survival was 26% (95% CI, 15.5% to 36.4%), survival was 22% (95% CI, 10.9% to 33.2%) in chemotherapy-naive patients and 40% (95% CI, 15.2% to 64.8%) in pretreated patients. Hematologic toxicity was mild, and there was no alopecia. The most common adverse events were asthenia, nausea/vomiting, and paraesthesia, and no treatment-related deaths were reported. CONCLUSION The raltitrexed and oxaliplatin combination is an active outpatient regimen in malignant mesothelioma and has an acceptable tolerability profile.
This paper references
10.1200/JCO.2000.18.11.2293
Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer.
K. Fizazi (2000)
10.1200/JCO.1988.6.3.527
Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers.
A. Alberts (1988)
10.1056/NEJM198507113130205
The treatment of cancer pain.
K. Foley (1985)
10.1016/S0959-8049(00)00139-8
Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma.
K. Fizazi (2000)
10.7326/0003-4819-96-6-746
Diffuse malignant mesothelioma. Prospective evaluation of 69 patients.
A. Chahinian (1982)
10.1378/CHEST.113.1_SUPPLEMENT.66S
A review of chemotherapy trials for malignant mesothelioma.
C. Ryan (1998)
10.1016/0959-8049(95)96182-D
933 Oxaliplatin (L-OHP®): Global safety in 682 patients (PTS)
S. Brienza (1995)
10.1016/S0959-8049(05)80168-6
Chemotherapy for ovarian cancer.
S. Kaye (1993)
10.1053/SONC.2002.30233
The emerging role of antifolates in the treatment of malignant pleural mesothelioma.
K. Fizazi (2002)
10.1200/JCO.1998.16.8.2739
Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.
Y. Bécouarn (1998)
10.1093/OXFORDJOURNALS.ANNONC.A010546
'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. 'Tomudex' International Study Group.
D. Cunningham (1996)
10.1016/0009-2797(72)90078-6
New platinum complexes with anti-tumour activity.
T. Connors (1972)
10.1378/CHEST.93.1.159
Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients.
E. Chailleux (1988)
10.1093/OXFORDJOURNALS.ANNONC.A010500
Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer.
P. Chollet (1996)
10.1016/S0140-6736(95)90462-X
Continuing increase in mesothelioma mortality in Britain
J. Peto (1995)
10.1097/00000421-199002000-00002
The Treatment of Malignant Mesothelioma of the Pleura: Review of a 5‐Year Experience, With Special Reference to Radiotherapy
D. Ball (1990)
Rationale for development of platinum analogs.
J. Burchenal (1979)
10.1016/0959-8049(95)00198-0
Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines.
L. Kelland (1995)
10.1200/JCO.1989.7.8.1157
Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients.
P. Ruffié (1989)
10.1016/S0022-5223(19)36577-8
The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial.
V. Rusch (1991)
10.1200/JCO.1999.17.1.25
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M. Byrne (1999)
10.1200/JCO.1996.14.3.1007
Chemotherapy in malignant pleural mesothelioma. A review.
S. T. Ong (1996)
10.1038/bjc.1998.421
Mature results from three large controlled studies with raltitrexed ('Tomudex').
D. Cunningham (1998)
10.1200/JCO.2000.18.16.2938
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
A. de Gramont (2000)
10.1002/1097-0142(20010401)91:7<1264::AID-CNCR1127>3.0.CO;2-X
Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma
W. Scheithauer (2001)
10.1002/AJIM.4700030305
Occupational exposure to asbestos: population at risk and projected mortality--1980-2030.
W. Nicholson (1982)



This paper is referenced by
10.1016/J.LUNGCAN.2006.01.002
Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1).
C. Pinto (2006)
10.1016/S1155-1968(10)53974-9
Traitement des pathologies tumorales du péritoine
D. Elias (2010)
10.1016/S0761-8425(06)71786-7
4.2. Chimiothérapie du mésothéliome pleural malin
T. Berghmans (2006)
10.1016/B978-012369448-5.50012-4
Targeting thymidylate synthase by antifolate drugs for the treatment of cancer
A. Jackman (2008)
Serie: Pleuraerkrankungen (6) Therapeutische Optionen beim malignen Pleuramesotheliom
M. Serke (2005)
10.1097/COC.0b013e3181cae90e
Phase II Study of Gemcitabine Plus Docetaxel as Second-Line Treatment in Malignant Pleural Mesothelioma: A Single Institution Study
Ioannis S Tourkantonis (2011)
10.1158/1078-0432.CCR-03-0157
The Role of α-Folate Receptor-Mediated Transport in the Antitumor Activity of Antifolate Drugs
D. Theti (2004)
10.1007/s00520-005-0837-0
Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso
P. Hollen (2005)
10.1093/ANNONC/MDI187
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.
C. Manegold (2005)
10.1016/j.ejso.2008.09.010
Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma.
H. Yano (2009)
10.3816/CLC.2006.N.003
Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid.
L. Krug (2006)
Advances in the Medical Treatment of Malignant Mesothelioma
K. Kuribayashi (2014)
10.1200/JCO.2007.14.7611
Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.
P. Jänne (2008)
10.1517/14728214.12.1.127
Emerging drugs for mesothelioma
G. Scagliotti (2007)
10.1016/J.CTRV.2007.01.009
Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review.
B. Stordal (2007)
10.1016/S1556-0864(15)30366-X
The Use of Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma: A Systematic Review and Practice Guideline
P. Ellis (2006)
10.1053/SONC.2002.30233
The emerging role of antifolates in the treatment of malignant pleural mesothelioma.
K. Fizazi (2002)
10.1016/S1556-0864(15)30351-8
Pemetrexed Alone or in Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program
P. Jänne (2006)
10.1016/S1877-1203(18)30005-3
Quels résultats de l’immunothérapie dans les tumeurs thoraciques rares ?
N. Girard (2018)
10.1016/J.LUNGCAN.2006.04.014
Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma.
G. Utkan (2006)
10.1097/00000441-200501000-00007
Malignant pleural mesothelioma.
R. Hughes (2005)
10.1007/0-387-28274-2_39
First-Line Chemotherapy for Malignant Pleural Mesothelioma
P. Jänne (2005)
10.1007/s11864-011-0152-6
Chemotherapy for Malignant Pleural Mesothelioma
L. Garland (2011)
Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study.
M. Ralli (2009)
Analysis o f F actors A ssociated W ith O utcome i n P atients W ith Malignant P eritoneal M esothelioma U ndergoing S urgical Debulking a nd I ntraperitoneal C hemotherapy
A. Feldman (2003)
10.1016/j.ctrv.2009.09.003
Second-line treatment for malignant pleural mesothelioma.
G. Ceresoli (2010)
10.1038/sj.onc.1209809
Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin–proteasome pathway as a therapeutic target in poor prognosis tumors
A. Borczuk (2007)
10.1586/14737140.5.2.231
Pemetrexed–cisplatin combination in mesothelioma
M. Reck (2005)
10.1016/j.lungcan.2015.06.018
Second line therapy in malignant pleural mesothelioma: A systematic review.
W. Buikhuisen (2015)
10.1016/J.HOC.2005.09.010
An overview of chemotherapy for mesothelioma.
L. Krug (2005)
10.1007/0-387-28274-2_40
Second-Line Chemotherapy
N. Pavlakis (2005)
10.1517/13543784.12.5.853
Pemetrexed and its emerging role in the treatment of thoracic malignancies
G. Scagliotti (2003)
See more
Semantic Scholar Logo Some data provided by SemanticScholar